The disproportionate impact of Mps1 inhibitors on PBRM1-deficient tumours was also evidenced by the fact that tumour growth of PBRM1 KO-derived tumours, but not that of parental B16-F10 derived tumours, was significantly reduced following treatment with Mps1 inhibitors (Fig. 7l-n and Supplementary Fig. 13h). Here, PBRM1 is linked to neoplasm.